Related Experiment Videos

Triiodothyronine (T3) effects on cardiovascular system in patients with heart failure

Alessandro Pingitore1, Giorgio Iervasi

  • 1Institute of Clinical Physiology, C.N.R., Pisa, Italy. pingi@ifc.cnr.it

Recent Patents on Cardiovascular Drug Discovery
|January 29, 2008
PubMed

Insights

Thyroid hormones play a vital role in heart failure. Studies show thyroid dysfunction negatively impacts heart failure patients, but synthetic triiodothyronine (T3) improved cardiac function safely.

Area of Science:

  • Cardiology
  • Endocrinology
  • Molecular Biology

Background:

  • Thyroid hormones (TH) have a physiological role in cardiovascular homeostasis.
  • Altered TH metabolism is linked to cardiovascular dysfunction, especially in heart failure.
  • Mild thyroid dysfunction negatively impacts heart failure prognosis.

Purpose of the Study:

  • To review the role of thyroid hormones in heart failure.
  • To discuss the effects of altered TH metabolism on cardiovascular function.
  • To evaluate the therapeutic potential of TH in heart failure management.

Main Methods:

  • Review of experimental studies on TH metabolism and cardiovascular effects.
  • Analysis of clinical studies on thyroid dysfunction in heart failure patients.
  • Examination of synthetic triiodothyronine (T3) administration in heart failure.

Main Results:

  • Altered TH metabolism affects cardiac histology, cardiomyocyte function, and myocardial contractility.
  • Subclinical hypothyroidism, subclinical hyperthyroidism, and low T3 syndrome worsen heart failure prognosis.
  • Synthetic T3 treatment improved cardiac function in heart failure patients without adverse effects.

Conclusions:

  • Thyroid hormone replacement therapy warrants further investigation for heart failure.
  • Large-scale, placebo-controlled trials are needed to confirm safety and efficacy of chronic TH treatment.
  • Understanding TH's role is crucial for managing heart failure patients.

Related Concept Videos

Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...